Novo Nordisk A/S $NVO Shares Sold by Zevin Asset Management LLC

Zevin Asset Management LLC cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 10.6% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 75,740 shares of the company’s stock after selling 8,951 shares during the quarter. Zevin Asset Management LLC’s holdings in Novo Nordisk A/S were worth $5,228,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the period. Bank of New York Mellon Corp raised its holdings in Novo Nordisk A/S by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company’s stock valued at $58,316,000 after buying an additional 47,804 shares during the period. Penserra Capital Management LLC raised its holdings in Novo Nordisk A/S by 29.7% in the first quarter. Penserra Capital Management LLC now owns 7,831 shares of the company’s stock valued at $543,000 after buying an additional 1,794 shares during the period. U.S. Capital Wealth Advisors LLC lifted its position in Novo Nordisk A/S by 26.6% during the first quarter. U.S. Capital Wealth Advisors LLC now owns 8,773 shares of the company’s stock valued at $609,000 after buying an additional 1,843 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC grew its stake in Novo Nordisk A/S by 12.8% during the first quarter. Linden Thomas Advisory Services LLC now owns 4,011 shares of the company’s stock worth $279,000 after buying an additional 456 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 16th. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday. Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. Finally, TD Cowen dropped their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $59.20.

Novo Nordisk A/S Stock Performance

NVO stock opened at $46.04 on Friday. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $112.52. The stock has a market capitalization of $205.56 billion, a price-to-earnings ratio of 12.66, a PEG ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The stock’s fifty day moving average is $55.54 and its two-hundred day moving average is $61.58.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.74 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.